Article
Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis.
Chemotherapy - 1 Jan 2016
Kang Eun Joo, Min Kyung Hoon, Hur Gyu Young, Lee Sung Yong, Shim Jae Jeong, Kang Kyung Ho, Oh Sang Cheul, Seo Jae Hong, Kim Jun Suk
Abstract excerpt
BACKGROUND: Despite the development of molecular research and targeted therapy, patients with wild-type epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC) still receive platinum doublet chemotherapy as the standard first-line treatment. We investigated the efficacy of first-line regimens in patients with wild-type EGFR nonsquamous NSCLC. METHODS: We retrospectively analyzed the efficacy of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.